PT - JOURNAL ARTICLE AU - Shiaelis, Nicolas AU - Tometzki, Alexander AU - Peto, Leon AU - McMahon, Andrew AU - Hepp, Christof AU - Bickerton, Erica AU - Favard, Cyril AU - Muriaux, Delphine AU - Andersson, Monique AU - Oakley, Sarah AU - Vaughan, Alison AU - Matthews, Philippa C. AU - Stoesser, Nicole AU - Crook, Derrick AU - Kapanidis, Achillefs N. AU - Robb, Nicole C. TI - Virus detection and identification in minutes using single-particle imaging and deep learning AID - 10.1101/2020.10.13.20212035 DP - 2022 Jan 01 TA - medRxiv PG - 2020.10.13.20212035 4099 - http://medrxiv.org/content/early/2022/08/16/2020.10.13.20212035.short 4100 - http://medrxiv.org/content/early/2022/08/16/2020.10.13.20212035.full AB - The increasing frequency and magnitude of viral outbreaks in recent decades, epitomized by the current COVID-19 pandemic, has resulted in an urgent need for rapid and sensitive diagnostic methods. Here, we present a methodology for virus detection and identification that uses a convolutional neural network to distinguish between microscopy images of single intact particles of different viruses. Our assay achieves labeling, imaging and virus identification in less than five minutes and does not require any lysis, purification or amplification steps. The trained neural network was able to differentiate SARS-CoV-2 from negative clinical samples, as well as from other common respiratory pathogens such as influenza and seasonal human coronaviruses. Additionally, we were able to differentiate closely related strains of influenza, as well as SARS-CoV-2 variants. Single-particle imaging combined with deep learning therefore offers a promising alternative to traditional viral diagnostic and genomic sequencing methods, and has the potential for significant impact.Competing Interest StatementThis study was supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance (NIHR200915), a partnership between the UK Health Security Agency (UKHSA) and the University of Oxford, and the NIHR Oxford Biomedical Research Centre (BRC). The report presents independent research. The views expressed are those of the author(s) and not necessarily those of the NIHR, UKHSA or the Department of Health and Social Care. The work was carried out using a wide-field microscope from Oxford Nanoimaging, a company in which A.N.K. is a co-founder and shareholder, and is being commercialised by OxDx Ltd., a company in which N.C.R. and N.S. are co-founders. Patent applications relating to the work have been submitted by N.C.R., A.N.K. and N.S. (PCT/GB2019/053073 and PCT/GB2021/050990). The authors declare no other competing interests. Funding StatementWe are grateful to Micron Oxford, funded by Wellcome Strategic Awards (091911 and 107457; PI Ilan Davis), for their loan of their microscope and to Nadia Halidi for her help with the instrument. This research was supported by a Royal Society Dorothy Hodgkin Research Fellowship DKR00620 and Research Grant for Research Fellows RGF\R1\180054 (N.C.R.), the University of Oxford COVID-19 Research Response Fund (N.C.R and A.N.K.), a BBSRC-funded studentship (N.S.), and Wellcome Trust grant 110164/Z/15/Z (A.N.K.). All data will be available upon request.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:North West-Greater Manchester South Research Ethics Committee [REC], REC Ref:19/NW/0730I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request.